In May 2025, a 4-year-old Pakistani girl with severe thalassemia has been successfully treated with a Chinese-developed gene-editing drug, marking the first time the technology has been used on a foreign minor. This drug is developed by CorrectSequence, a ShanghaiTech-incubated company, treating a total number of over 20 patients.
More details about the story can be found on China Daily and Shanghai Daily.